Cuprina MENA Secures Exclusive License for Medicinal Leeches in GCC Countries and Completes Lab for Chronic Wound Therapy in Saudi Arabia

Reuters
06-04
Cuprina MENA Secures Exclusive License for Medicinal Leeches in GCC Countries and Completes Lab for Chronic Wound Therapy in Saudi Arabia

Cuprina MENA Co. Ltd, a 49%-owned associate of Cuprina Holdings (Cayman) Ltd, has completed the establishment of a laboratory in Saudi Arabia designed to manufacture MEDIFLY maggot debridement therapy for chronic wound treatment. This new facility will supply the therapy throughout the Middle East and North Africa region. Additionally, Cuprina MENA has acquired exclusive rights to market medicinal leeches in the Gulf Cooperation Council countries, a treatment increasingly used for medical conditions such as venous congestion and to enhance tissue healing post-surgery. These strategic advancements are expected to broaden Cuprina's market presence in the MENA and GCC regions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9463107-en) on June 04, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10